- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates | 1 | RTTNews | ||
| 10.11. | Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights | 120 | GlobeNewswire (Europe) | Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish... ► Artikel lesen | |
| 10.11. | Passage BIO, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11. | Passage BIO, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.09. | Passage BIO, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Guggenheim lowers Passage Bio stock price target to $10 from $40 | 3 | Investing.com | ||
| 14.08. | Canaccord Genuity lowers Passage Bio stock price target to $67 from $260 | 2 | Investing.com | ||
| PASSAGE BIO Aktie jetzt für 0€ handeln | |||||
| 12.08. | Passage Bio GAAP EPS of -$2.96 beats by $1.08 | 1 | Seeking Alpha | ||
| 12.08. | Passage BIO, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 12.08. | Passage BIO, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.07. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.07. | Passage Bio to implement 1-for-20 reverse stock split | 1 | Seeking Alpha | ||
| 10.07. | Passage Bio announces 1-for-20 reverse stock split to regain compliance | 1 | Investing.com | ||
| 10.07. | Passage Bio: Aktienzusammenlegung soll NASDAQ-Anforderungen erfüllen | 2 | Investing.com Deutsch | ||
| 10.07. | Passage Bio Announces 1-for-20 Reverse Stock Split | 349 | GlobeNewswire (Europe) | PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. ("Passage Bio" or the "Company") (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients... ► Artikel lesen | |
| 23.06. | Passage Bio reports updated data on PBFT02 for FTD treatment | 1 | Investing.com | ||
| 23.06. | Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update | 296 | GlobeNewswire (Europe) | PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose... ► Artikel lesen | |
| 23.06. | Passage BIO, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights | 208 | GlobeNewswire (Europe) | Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,30 | +0,63 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CUREVAC | 4,182 | -2,24 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| AMGEN | 276,75 | -0,04 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,608 | +0,07 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 148,65 | -0,57 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| MAINZ BIOMED | 1,030 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,000 | +0,68 % | This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street | ||
| INTELLIA THERAPEUTICS | 7,654 | -1,67 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 58,00 | -0,85 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,384 | -1,24 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,470 | 0,00 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,275 | -0,33 % | Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,36 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| EXELIXIS | 35,420 | +0,60 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| CARDIOL THERAPEUTICS | 0,893 | +2,29 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen |
Das Unternehmen PASSAGE BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,105 (+1,07 %) liegt der Kurs bei 9,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASSAGE BIO INC finden Sie auf Wallstreet Online.